Company intelligence / Profile preview
Sublimity Therapeutics
Dublin, Ireland
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Sublimity Therapeutics has developed a proprietary oral drug delivery technology called SmPill®, which enables targeted delivery of small molecules and potentially peptides/biologics to the GI tract. Their lead candidate, ST‑0529—an oral colon-targeted cyclosporine—has advanced into a Phase IIb clinical trial for moderate-to-severe ulcerative colitis. The company plans to expand this approach into additional IBD subtypes and other immune-mediated diseases such as psoriasis and multiple sclerosis. No published pivotal results yet; ongoing clinical development.[2][3][4]
- Therapeutic areas
- GastroenterologyNeurologyImmunologyDermatology
- Modalities
- Small molecules (e.g., cyclosporine in SmPill formulation)Peptides (potentially via platform)Biologics/proteins/antibodies (potentially via platform)[4]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sublimity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sublimity Therapeutics.